Inclusion Criteria:

          -  Age ≥18 years.

          -  Have histologically or cytologically - proven cancer of the pancreas or colon.

          -  Have tumor lesions amenable to repeated biopsy, and patient's acceptance to have a
             tumor biopsy of an accessible lesion at baseline and on treatment if the lesion can be
             biopsied with acceptable clinical risk (as judged by the investigator).

          -  Measurable disease as per RECIST 1.1.

          -  Have sufficient and accessible tissue for NGS and immune-phenotyping.

          -  Have not received any prior systemic therapy in the metastatic setting for PDA or CRC.
             Patients who have received adjuvant chemotherapy >12 months prior to the diagnosis of
             metastatic disease may be eligible.

          -  ECOG performance status 0.

          -  Life expectancy of greater than 6 months.

          -  Patients must have adequate organ and marrow function defined by study-specified
             laboratory tests prior to initial study drug.

          -  Woman of childbearing potential must have a negative pregnancy test and follow
             contraceptive guidelines as defined per protocol.

          -  Men must use acceptable form of birth control while on study.

          -  Ability to understand and willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Is a candidate for definitive surgical resection.

          -  Is unwilling or unable to undergo standard of care therapy.

          -  Known history or evidence of brain metastases and/or leptomeningeal spread.

          -  Prior treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1,
             anti-PD-L2, anti-CTLA4, etc.).

          -  Receiving active immunosuppressive agents or chronic use of systemic corticosteroids
             within 14 days of vaccine treatment.

          -  Has active autoimmune disease that has required systemic treatment in the past 5
             years, or a documented history of clinically severe autoimmune disease, or a syndrome
             that requires systemic steroids or immunosuppressive agents.

          -  Known history or concurrent interstitial lung disease.

          -  Has a pulse oximetry < 95% on room air.

          -  Requires the use of home oxygen.

          -  Infection with HIV or hepatitis B or C.

          -  Uncontrolled intercurrent illness including, but not limited to, uncontrolled
             infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia,
             metastatic cancer, or psychiatric illness/social situations that would limit
             compliance with study requirements.

          -  Has been diagnosed with another cancer or myeloproliferative disorder within the past
             5 year.

          -  Has had surgery within 28 days of dosing of investigational agent, excluding minor
             procedures (dental work, skin biopsy, etc.), celiac plexus block, and biliary stent
             placement.

          -  Has received any non-oncology live vaccine therapy used for prevention of infectious
             diseases within 28 days of study treatment.

          -  If at the time of signing informed consent, a regular user (including "recreational
             use") of any illicit drugs or other substance abuse (including alcohol) that could
             potentially interfere with adherence to study procedures or requirements.

          -  Any other sound medical, psychiatric, and/or social reason as determined by the
             Investigator.

          -  Unwilling or unable to follow the study schedule for any reason.

          -  Are pregnant or breastfeeding.

          -  Any radiological or clinical pleural effusions or ascites.

          -  Any peritoneal involvement by the tumor.

          -  History of malignant small bowel obstruction.

          -  On parenteral nutrition.

          -  Any liver metastasis greater than 3 cm or greater than 5 liver metastases.

          -  Known or suspected hypersensitivity to Hiltonol.